Needham Reiterates Buy on Praxis Precision Medicine, Maintains $145 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintains a $145 price target.
August 14, 2024 | 9:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Praxis Precision Medicine and maintains a $145 price target.
The reiteration of a Buy rating and a high price target of $145 by a reputable analyst is likely to positively impact the stock price of Praxis Precision Medicine in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100